Summary

Odanacatib is a selective, potent, and reversible cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This article discusses results of A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK0822) in Postmenopausal Women Previously Treated with Alendronate. The trial found odanacatib to be safe and effective for increasing bone mineral density in postmenopausal women previously treated with alendronate.